BR112014014973A2 - preparações contendo emodepside amorfo - Google Patents

preparações contendo emodepside amorfo

Info

Publication number
BR112014014973A2
BR112014014973A2 BR112014014973A BR112014014973A BR112014014973A2 BR 112014014973 A2 BR112014014973 A2 BR 112014014973A2 BR 112014014973 A BR112014014973 A BR 112014014973A BR 112014014973 A BR112014014973 A BR 112014014973A BR 112014014973 A2 BR112014014973 A2 BR 112014014973A2
Authority
BR
Brazil
Prior art keywords
preparations
emodepside
amorphous emodepside
amorphous
containing amorphous
Prior art date
Application number
BR112014014973A
Other languages
English (en)
Inventor
Hamann Hans-Jürgen
Kleinebudde Peter
Lange Petra
Kanikanti Venkata-Rangarao
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47358491&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014014973(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of BR112014014973A2 publication Critical patent/BR112014014973A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Abstract

resumo da patente de invenção para: “preparações contendo emodepside amorfo” a invenção refere-se a preparações contendo emodepside amorfo em uma matriz de polivinilpirrolidona, aos produtos farmacêuticos que contêm estas preparações e ao respectivo uso contra endoparasitas em animais ou seres humanos.
BR112014014973A 2011-12-21 2012-12-18 preparações contendo emodepside amorfo BR112014014973A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11194878 2011-12-21
PCT/EP2012/075909 WO2013092558A1 (de) 2011-12-21 2012-12-18 Zubereitungen enthaltend amorphes emodepsid

Publications (1)

Publication Number Publication Date
BR112014014973A2 true BR112014014973A2 (pt) 2017-06-13

Family

ID=47358491

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014973A BR112014014973A2 (pt) 2011-12-21 2012-12-18 preparações contendo emodepside amorfo

Country Status (24)

Country Link
US (3) US9539331B2 (pt)
EP (1) EP2793861B1 (pt)
JP (1) JP6185930B2 (pt)
KR (2) KR101978620B1 (pt)
CN (2) CN108187028A (pt)
AU (2) AU2012357848C1 (pt)
BR (1) BR112014014973A2 (pt)
CA (1) CA2859787C (pt)
CL (1) CL2014001637A1 (pt)
CO (1) CO6990713A2 (pt)
CR (1) CR20140293A (pt)
DO (1) DOP2014000140A (pt)
EC (1) ECSP14005917A (pt)
ES (1) ES2734352T3 (pt)
HK (1) HK1255536A1 (pt)
IL (1) IL233183B (pt)
MX (2) MX368209B (pt)
MY (1) MY175307A (pt)
NI (1) NI201400065A (pt)
PH (2) PH12014501438B1 (pt)
RU (2) RU2651761C2 (pt)
UA (1) UA115232C2 (pt)
WO (1) WO2013092558A1 (pt)
ZA (1) ZA201404529B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368209B (es) 2011-12-21 2019-09-24 Bayer Pharma Ag Star Preparaciones que comprenden emodepsido amorfo.
SG10202103403SA (en) 2015-05-20 2021-05-28 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic depsipeptide compounds
CN108699052B (zh) 2015-12-28 2022-04-29 勃林格殷格翰动物保健美国公司 驱虫缩酚酸肽化合物
CA3044038A1 (en) 2016-11-16 2018-05-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic depsipeptide compounds
CN114195732A (zh) * 2022-01-04 2022-03-18 丽珠集团福州福兴医药有限公司 一种艾默德斯的单晶型iii及其制备方法
CN115444927B (zh) * 2022-09-19 2023-06-02 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 艾默德斯在制备治疗三阴性乳腺癌的药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE211466T1 (de) * 1992-03-17 2002-01-15 Fujisawa Pharmaceutical Co Depsipeptide, herstellung und anwendung
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
DE10031044A1 (de) 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
DE102005011779A1 (de) * 2005-03-11 2006-09-14 Bayer Healthcare Ag Endoparasitizide Mittel
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
RU2315614C1 (ru) * 2006-04-19 2008-01-27 Бийтемир Ахмедович Султанбеков Средство "грепол" и способ применения его при паразитарных заболеваниях
RU2425825C2 (ru) * 2007-02-09 2011-08-10 Пфайзер Лимитед Амидоацетонитрильные производные, содержащие их фармацевтические композиции и их применение в изготовлении лекарственного средства
DE102008022520A1 (de) 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
EP2355802A1 (de) * 2008-11-14 2011-08-17 Ratiopharm GmbH Intermediate und orale darreichungsformen enthaltend lenalidomid
DE102009012423A1 (de) * 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Zubereitung auf Ölbasis
MX368209B (es) 2011-12-21 2019-09-24 Bayer Pharma Ag Star Preparaciones que comprenden emodepsido amorfo.

Also Published As

Publication number Publication date
MX368209B (es) 2019-09-24
MX2014007224A (es) 2014-09-22
KR20180084141A (ko) 2018-07-24
JP6185930B2 (ja) 2017-08-23
NI201400065A (es) 2015-12-10
KR101978620B1 (ko) 2019-08-28
NZ625817A (en) 2016-08-26
US10251932B2 (en) 2019-04-09
MX356094B (es) 2018-05-14
AU2012357848B2 (en) 2018-01-04
KR20140107296A (ko) 2014-09-04
UA115232C2 (uk) 2017-10-10
CR20140293A (es) 2014-07-14
CO6990713A2 (es) 2014-07-10
HK1255536A1 (zh) 2019-08-23
CN104023710A (zh) 2014-09-03
EP2793861B1 (de) 2019-05-01
DOP2014000140A (es) 2014-07-31
RU2018105003A (ru) 2019-02-22
ES2734352T3 (es) 2019-12-05
US20170182118A1 (en) 2017-06-29
CA2859787A1 (en) 2013-06-27
AU2018202376B2 (en) 2019-06-20
PH12018500368A1 (en) 2018-07-23
US20180153957A1 (en) 2018-06-07
RU2018105003A3 (pt) 2021-06-11
US9539331B2 (en) 2017-01-10
WO2013092558A1 (de) 2013-06-27
PH12014501438A1 (en) 2014-10-08
AU2012357848A1 (en) 2014-07-10
CA2859787C (en) 2020-09-08
IL233183A0 (en) 2014-07-31
RU2761529C2 (ru) 2021-12-09
JP2015502377A (ja) 2015-01-22
MY175307A (en) 2020-06-18
US20140371139A1 (en) 2014-12-18
CN108187028A (zh) 2018-06-22
RU2014129620A (ru) 2016-02-10
RU2651761C2 (ru) 2018-04-23
AU2012357848C1 (en) 2018-07-19
AU2018202376A1 (en) 2018-04-26
EP2793861A1 (de) 2014-10-29
IL233183B (en) 2020-01-30
PH12014501438B1 (en) 2014-10-08
KR101979049B1 (ko) 2019-05-15
ZA201404529B (en) 2017-06-28
ECSP14005917A (es) 2015-12-31
CL2014001637A1 (es) 2014-11-21

Similar Documents

Publication Publication Date Title
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
BR112014014973A2 (pt) preparações contendo emodepside amorfo
CY1119518T1 (el) Τροποποιημενα αντιγονα φυματιωσης
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BRPI1006825A2 (pt) compostos pró-neurogênicos
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MX2010005385A (es) Medicamentos topicos para la terapia antimicotica.
CL2014003225A1 (es) Composición que comprende un agente de control biológico y un fungicida.
WO2011127070A3 (en) IRE-1α INHIBITORS
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
IN2015DN02729A (pt)
BRPI1012066A2 (pt) composição para o cuidado oral , e, métodos para preparar a composição para o cuidado oral e para administrar um composto de zinco a um indivíduo animal ou humano em necessidade do mesmo
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
BRPI0911511B8 (pt) formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo
BRPI0506888A (pt) composições de suplemento lìquido compreendendo um ou mais medicamentos
BR112013003530A2 (pt) ''produto farmacêutico, kit, uso e preparações''
BRPI1008802A2 (pt) composição, vetor e formulação farmacêutica para o uso na prevenção ou tratamento de alergia a pólen de grama por tolerização, produto, e, método in vitro para determinar se as células t reconhecem uma composição
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
BR112015010528A2 (pt) piridiloxialquilcarboxamidas e seu uso como endoparasiticidas e nematicidas
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CL2013001853A1 (es) Bacteria no patogena gram negativa perteneciente a la clase betaproteobacteria y subfamilia neisseriaceae; extracto que la comprende; composicion que comprende a la bacteria o al extracto; y su uso para tratar o prevenir trastornos inflamatorios dermatologicos.
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
WO2015100370A3 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]